In all actual clinical guidelines, dihydropyridine calcium channel blockers (CCBs) belong to
the recommended first line antihypertensive drugs to treat essential hypertension. Several …

Objective: In randomized controlled trials lercanidipine was well tolerated, with very few
treatment-related adverse events typical of dihydropyridine calcium antagonists (eg flushing …

Abstract (±) Lercanidipine hydrochloride (HCl)(Zanidip) is an antihypertensive drug
structurally related to dihydropyridine calcium-entry blockers: lercanidipine is weakly basic …

Essential hypertension is characterized by impaired endothelium-dependent vasodilation.
The present study was designed to test whether antihypertensive treatment with the calcium …

The efficacy of the new once-daily dihydropyridine calcium antagonist, lacidipine, in
reducing ambulatory intraarterial blood pressure (BP) was examined in 12 untreated …

We compared antihypertensive efficacy and safety of a single administration of equipotent
doses of lacidipine versus nifedipine in the hypertensive urgencies. Twenty-nine …

We investigated the effect of lacidipine on 100-mM K+-evoked contractions and on 100-mM
K+-evoked 45 Ca 2+ influx in rat aorta. Moreover, we compared the effect of prolonged …

Background: Results from clinical studies suggest that the dihydropyridine calcium channel
blocker (CCB) lercanidipine may be associated with a lower incidence of peripheral edema …

Systemic hypertension is a major global problem contributing to enormous disease burden,
premature morbidity and mortality. A substantial majority of hypertensive patients require …

Lipophilic dihydropyridines have many theoretical and practical clinical advantages owing to
their long permanence at the cell membrane. They have a greater chance of smoothly and …